NCT07322432 · VapeAway
The CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction
(CONQUER)
What this study is about
This clinical trial evaluates the VapeAway system, a novel, multi-modal intervention designed to address the multifaceted nature of vaping addiction. VapeAway combines progressive nicotine tapering via proprietary filters, behavioral substitution with a sensory device (Fix Bar), and structured digital support.
View original scientific description
This clinical trial evaluates the VapeAway system, a novel, multi-modal intervention designed to address the multifaceted nature of vaping addiction. VapeAway combines progressive nicotine tapering via proprietary filters, behavioral substitution with a sensory device (Fix Bar), and structured digital support. The purpose of this research is to evaluate the efficacy and safety of the investigational VapeAway system, a multi-component behavioral and nicotine-reduction intervention, for promoting cessation of nicotine-containing e-cigarette use in motivated adults. The primary objective is to determine if the VapeAway program can achieve a Continuous Abstinence Rate (CAR) of at least 25% at 30 days post-intervention completion, a rate which will be statistically compared to the historical spontaneous cessation rate of approximately 7%. Secondary objectives include assessing reductions in biochemical nicotine exposure (cotinine), vaping frequency, withdrawal symptoms, and electronic cigarette dependence, as well as characterizing the safety and tolerability profile of the intervention. Participants will be asked to follow the VapeAway system (filters, Fix Bar and timeout periods) as prescribed by the protocol for about 42 days. During this time, participants should keep track of vaping sessions throughout the trial.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Age: Adults aged 21 years and older
- Current Vaping Behavior: Daily or near-daily use (≥5 days/week or at least 20 days per month) of nicotine-containing e-cigarettes for at least the past 3 months.
- Motivation and desire to quit as determined by all of the following three assessment tools:
- Score of 4 or 5 on all 5-point Likert-type scale questions (see appendix)
- Score of 6 or 7 on Motivation To Stop Scale (MTSS) (see appendix)
- Participants must be classified in the Preparation stage of the Transtheoretical Model of behavior change (see appendix)
- Saliva Cotinine level ≥ 10 ng/ml
- Penn State Electronic Cigarette Dependence Index (PSECDI) of at least 4 and above
- Willingness to participate in the study and all study requirements
- Willingness to not use any other nicotine-containing products for the duration of the study
- Ability to attend visits and provide informed consent
Exclusion criteria
- Mental Health Concerns with a score above the following thresholds:
- PHQ-2 score ≥ 2 (see appendix)
- GAD-2 score ≥ 2 (see appendix)
- Use of Other Tobacco or Nicotine Products:
- Use of any nicotine products except for vaping, including combustible tobacco (e.g., cigarettes) or other non-e-cigarette nicotine delivery systems within the past 30-days
- Current Substance or alcohol Use Disorder:
- Self-reported or medically diagnosed substance use disorder (excluding nicotine), unless in sustained remission (\>12 months).
- Illicit drug use in the past 60 days
- Screening positive for alcohol use disorder in past year
- Medical Contraindications:
- Any serious medical condition or medication that would contraindicate participation in a behavioral cessation trial (to be defined and assessed by study physician or PI).
- Pregnant or breastfeeding
- Symptomatic cardiovascular disease
- Participation in another smoking/vaping cessation trial
Where
- New York, New York
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jan 7, 2026 · Source of record for eligibility and locations